98
edits
Difference between revisions of "Lung carcinoma with ALK rearrangement"
Jump to navigation
Jump to search
Lung carcinoma with ALK rearrangement (view source)
Revision as of 03:06, 21 September 2017
, 03:06, 21 September 2017→General
| Line 6: | Line 6: | ||
**Typically seen in nonsmokers and younger age patients. | **Typically seen in nonsmokers and younger age patients. | ||
**Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal | last1 = Crystal | first1 = AS. | last2 = Shaw | first2 = AT. | title = New targets in advanced NSCLC: EML4-ALK. | journal = Clin Adv Hematol Oncol | volume = 9 | issue = 3 | pages = 207-14 | month = Mar | year = 2011 | doi = | PMID = 21475126 }}</ref> | **Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal | last1 = Crystal | first1 = AS. | last2 = Shaw | first2 = AT. | title = New targets in advanced NSCLC: EML4-ALK. | journal = Clin Adv Hematol Oncol | volume = 9 | issue = 3 | pages = 207-14 | month = Mar | year = 2011 | doi = | PMID = 21475126 }}</ref> | ||
***Resistance to ALK inhibitors may occur due mutations in kinase domain. | |||
***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref name="pmid24670165">{{Cita publicación | apellido = Shaw | nombre = AT. | coautores = DW. Kim, R. Mehra, DS. Tan, E. Felip, LQ. Chow, DR. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, GJ. Riely | título = Ceritinib in ALK-rearranged non-small-cell lung cancer. | publicación = N Engl J Med | volume = 370 | número = 13 | páginas = 1189-97 | mes = Mar | año = 2014 | doi = 10.1056/NEJMoa1311107 | pmid = 24670165 }}</ref> | |||
==Microscopic== | ==Microscopic== | ||